E
2.32
0.52 (28.61%)
| Penutupan Terdahulu | 1.80 |
| Jumlah Dagangan | 9,419,888 |
| Harga / Buku (P/B) | 0.530 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.63 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.16% |
| Nisbah Semasa (MRQ) | 12.66 |
| Aliran Tunai Operasi (OCF TTM) | -75.39 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -47.37 M |
| Pulangan Atas Aset (ROA TTM) | -20.35% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.97% |
AISkor Stockmoo
| Nilai 35% | 0.0 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | 0.0 |
| Masa 35% | 1.2 |
| AI Technical info | NA |
| Osilator Teknikal info | 2.0 |
| Purata Bergerak Teknikal info | 0.0 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Sentimen Berita info | NA |
| Persekitaran | ×0.79 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -23.0% |
| Persetujuan Tonggak | ×1.00 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | -0.1 |
| Skor Akhir | 0.33 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | enGene Therapeutics Inc. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ENGN | - | - | - | 0.530 |
| TRML | 1 B | - | - | 4.76 |
| IOVA | - | - | - | 4.60 |
| DBVT | - | - | - | 4.87 |
| JANX | - | - | - | 0.810 |
| CRNX | - | - | - | 7.56 |
|
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 13.63% |
| % Dimiliki oleh Institusi | 77.57% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 11 Nov 2026 | Yahoo Finance |
enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC
BOSTON & MONTREAL, November 11, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced updated results from the pivotal Cohort 1 of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as… |
| 11 Nov 2026 | Yahoo Finance |
enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones
BOSTON & MONTREAL, November 11, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN) ("enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced the appointments of Erik T. Goluboff, MD, MBA as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative… |
| 06 Nov 2026 | Yahoo Finance |
enGene to Participate in Upcoming Investor Conferences
BOSTON & MONTREAL, November 06, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences:… |
| 16 Oct 2026 | Yahoo Finance |
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
enGene (NASDAQ:ENGN) used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse, while community urologists discussed the treatment burden facing patients with high-risk non-muscle… |
| 13 Oct 2026 | Yahoo Finance |
enGene to Host KOL Webinar on October 15, 2026
BOSTON & MONTREAL, October 13, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it will host a webinar on Thursday, October 15, 2026 at 10:00 AM ET that will provide greater detail on the… |
| 08 Sep 2026 | Yahoo Finance |
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL, September 08, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates. |
| 13 Aug 2026 | Yahoo Finance |
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
enGene (NASDAQ:ENGN) outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystecto… |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |